Stability and DNA alkylation rates of the simplest functional analogues of CC-1065, para-hydroxy and para-amino phenethyl bromides

Chemico-Biological Interactions

Volumn 117, Issue 1, 1999, Pages 83-94

  Shalders, Robyn L ^a,b   Blanch, Gregory ^b   Brown, Christopher L ^b   Young, David J ^b   Prakash, Arungundrum S ^a  

^a University of Queensland and Queensland Alliance for Environmental Health Sciences   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

CC 1065; CPI subunit; DNA alkylation; Sequence selectivity

Indexed keywords

DOUBLE STRANDED DNA; RACHELMYCIN DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA ALKYLATION; DRUG STABILITY; DRUG SYNTHESIS; DRUG TOXICITY; NONHUMAN;

ADENINE; ALKYLATION; ANTIBIOTICS, ANTINEOPLASTIC; BASE SEQUENCE; COMPUTER SIMULATION; DNA; HELA CELLS; HUMANS; HYDROCARBONS, BROMINATED; HYDROXYBENZOIC ACIDS; INDOLES; LEUCOMYCINS; MODELS, CHEMICAL; MOLECULAR SEQUENCE DATA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032918083     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(98)00102-1     Document Type: Article

References (24)

1. Lee C.S., Gibson N.W. Nucleotide preferences for DNA interstrand cross linking induced by the cyclopropylpyrroloindole analogue U-77,779. Biochemistry. 32:1993;2592-2600.
2. Shamdas G.J., Alberts D.S., Madiano M. et al. Phase I study of Adozelesin (U-73,975) in patients with solid tumours. Anticancer Drugs. 5(1):1994;10-14.
3. Foster B.J., LoRusso P.M., Poplin E. et al. Phase I trials of Adozelesin using treatment schedule of daily ×5 every 3 weeks. Invest. New Drugs. 13(4):1996;321-326.
4. Burris H.A., Dieras V.C., Tunca M. et al. Phase I study with the DNA sequence-specific agent Adozelesin. Anticancer Drugs. 8(6):1997;588-596.
5. Wolff I., Bench K., Beijnen J.H. et al. Phase I clinical and pharmacokinetic study of Carzelesin (U-80244) given daily of 5 consecutive days. Clin. Cancer Res. 2(10):1996;1717-1723.
6. C.A. Carter, W.R. Wand, L.H. Li, T.F. Dekoning, J.P. McGovren, J. Plowman, Preclinical antitumour activity of bizelesin in mice, Clin. Cancer Res., 2(7), (1996) 1143-1149.
7. Volpe D.A., Tomaszewski J.E., Parchment R.E., Garg A., Flora K.P., Murphy M.J., Grieshaber C.K. Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells. Cancer Chemother. Pharmacol. 39(1-2):1996;143-149.
8. Boger D., Johnson D.S. CC-1065 and the duocarmycins: understanding their biological function through mechanistic studies. Angew. Chem. Int. Ed. Engl. 35:1996;1438-1474.
9. White R.H., Parsons P.G., Prakash A.S., Young D.J. The in vitro cytotoxicity and DNA alkylating ability of the simplest functional analogues of the seco CC-1065 alkylating subunit. Biorg. Med. Chem. Lett. 5:1995;1869-1874.
10. Baird R., Winstein S. Neighboring carbon and hydrogen. LI. Dienones from Ar-3 participation. Isolation and behaviour of spiro(2,5) octa-1,4-diene-3-one. J. Am. Chem. Soc. 85:1963;567-578.
11. Ashley J.N., Barber H.J., Ewins A.J., Newbery G., Self A.D.H. Chemotherapeutic comparison of the trypanocidal action of some aromatic diamines. J. Chem. Soc. 64:1942;103-116.
12. Prakash A.S., Denny W.A., Gourdie T.A., Valu K.K., Woodgate P.D., Wakelin L.P.G. DNA directed alkylating ligands as potential antitumour agents: sequence specificity of alkylation by intercalating aniline mustards. Biochemistry. 29:1990;9799-9807.
13. Hayes M.T., Bartley J., Parsons P.G., Prakash A.S. Mechanism of action of fotemustine, a new chloroethylnitrosourea anticancer agent: evidence for the formation of two DNA-reactive intermediates contributing to cytotoxicity. Biochemistry. 36(35):1997;10646-10654.
14. Mohamadi F., Richards N.G.J., Guida W.C. et al. Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Comp. Chem. 11:1990;440.
15. Still W.C., Tempczyk A., Hawley R.C., Hendrickson T. Macromodel - An integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Am. Chem. Soc. 112:1990;6127.
16. Hanlon S., Wong L., Pack G.R. Proton equilibria in the minor groove of DNA. Biophys. J. 72:1997;291-300.
17. Lamm G., Pack G.R. Acidic domains around nucleic acids. Proc. Natl. Acad. Sci. USA. 87(22):1990;9033-9036.
18. Macleod M.C. The importance of intercalation in the covalent binding of benzo(a)pyrene diol epoxide to DNA. J. Theor. Biol. 142(1):1990;113-122.
19. Bolt H.M., Capellmann M., Jelitto B., Hindermeier U., Kirkovsky L.I. Differential reactivities of the mono- and diepoxide of 1,3-butadiene. Toxicology. 113(13):1996;294-296.
20. Prakash A.S., Pereira T.N., Smith B.L., Shaw G., Seawright A.A. Mechanism of bracken fern carcinogenesis: evidence for H-ras activation via initial adenine alkylation by ptaquiloside. Nat. Toxins. 4:1996;221-227.
21. Carlson R.M. Assessment of the propensity for covalent binding of electrophiles to biological substrates. Environ. Health Perspect. 87:1990;227-232.
22. Boger D.L., Johnson D.J. CC-1065 and the duocarmycins: understanding their biological function through mechanistic studies. Angew. Chem. Int. Ed. Engl. 35:1996;1438-1474.
23. Dong Y., Berners-Price S.J., Thorburn D.R. et al. Serine protease inhibition and mitochondrial dysfunction associated with cisplatin resistance in human tumour cell lines: targets for therapy. Biochem. Pharmacol. 53:1997;1673-1682.
24. Tercel M., Denny W.A., Wilson W.R. Nitrogen and sulphur analogues of the seco-CI alkylating agent: synthesis and cytotoxicity. Bioorg Med. Chem. Lett. 6(22):1996;2735-2740.